Adrian V. Lee

The paper develops a novel mouse cell line model of invasive lobular breast carcinoma that recapitulates human tumor phenotype and immune microenvironment, offering a preclinical platform for therapy evaluation.

The paper identifies increased GPCR pathway activity in breast cancer ovarian metastases and links it to migration and F-actin reorganization through CaSR.

This study shows that chronic inflammation and hormonal changes in older women create a tumor-permissive environment for ER+ breast cancer by increasing local estradiol and immune dysfunction.

This study shows HER2 mutations drive HER2/HER3 hyperactivation in ILC, making it sensitive to HER2/HER3-targeting ADCs, and highlights the synergy between T-DXd and P-DXd.

This study shows that ER-positive ILC xenograft models replicate metastatic patterns and endocrine response of human invasive lobular breast carcinoma.

This study benchmarks 12 scRNA-seq CNV inference methods across 28 datasets, finding allele-aware tools perform better with high-quality allelic data, while expression-centric tools are reliable with raw data.

This study shows that elevated cfDNA and fragment shortening in cancer are due to saturated hepatic clearance, not tumor burden alone.

This study identifies and characterizes patient-derived xenograft models of invasive lobular breast carcinoma using multi-omics and histopathology, finding seven ILC PDX models with CDH1 mutations and low CDH1 expression.

This study identifies nitro-oleic acid (OA-NO2) as a compound that re-sensitizes PARPi-resistant TNBC cells to PARPi by targeting p62 and inhibiting autophagy.

This study establishes patient-derived organoids (PDOs) for HNSCC drug response testing, integrating AI-driven histopathology and multi-omics analysis to create a scalable preclinical model.

The paper describes the Hope for Others rapid autopsy program for metastatic breast cancer, detailing its protocols, sample collection, and findings on metastasis research and model development.

This study identifies RET as a druggable target in estrogen receptor-positive breast cancer brain metastases and shows that Pralsetinib inhibits RET-driven metastatic properties.

This study investigates FGFR4's role in endocrine resistance in ER+ breast cancer and finds it does not generally mediate resistance, though HER2-like subtypes may respond to FGFR4 inhibition.

This paper develops a high-throughput screening method to identify drugs targeting polyploid giant cancer cells in breast cancer, combining empirical assays with a machine learning model for virtual screening.

EstroGene2.0 is a multi-omic database that compiles data on estrogen receptor responses and resistance in breast cancer, revealing diverse transcriptomic changes and identifying key targets.

The paper identifies S100A11 as a factor promoting macrophage recruitment in ER+ breast cancer through single-cell RNA-sequencing analysis and functional experiments.

This study identifies the MRTFA/SRF pathway as a regulator of quiescence in cancer and shows that inhibiting it induces quiescence and reduces tumor growth.

The paper introduces MICA, a method to detect multi-class biomarkers across multiple transcriptomic studies, showing improved accuracy and biological insights in both bulk and single-cell data.

This study shows that Hrq1/RECQL4 regulates DNA intrastrand crosslink repair and its misregulation contributes to genomic instability in cancer.

The paper develops a computational model of IGF1R and InsR signaling to reveal context-dependent Akt activity in luminal breast cancer cells and identifies RPS6K as a key regulator.

This study sequenced 41 stage IV breast cancer samples using MammaSeq to identify 59 genomic alterations, including 49 SNVs and 10 CNVs, with 8 having clinical significance.

The paper describes a bioinformatics support service model for biomedical researchers, detailing its four facets and outcomes from a survey of University of Pittsburgh researchers.

The paper identifies ID1 and ID3 as novel drivers of anchorage-independent growth in invasive lobular breast cancer through proteomic and transcriptomic profiling.